Head-to-head evidence
Lecanemab vs Remternetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
Lecanemab · Leqembi
Marketed by Eisai and partners
NCT01767311 · Phase 2 · completed
Randomized, triple-masked phase 2b in early Alzheimer's disease (856 participants). The Bayesian primary analysis of the ADCOMS composite at 12 months estimated a 63.8% posterior probability of meaningful benefit for the highest dose, short of the study's prespecified success criterion, so the primary endpoint was not met.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
Remternetug
Developed by Eli Lilly
NCT05463731 · Phase 3 · completed
The study randomized 1,667 participants to remternetug or matching placebo, with participants and investigators blinded during the main treatment period. Its primary endpoint was amyloid plaque clearance measured by PET, a biomarker endpoint, and the registry does not report whether the week-52 comparison was favorable or statistically significant.
Next expected readout: April 2029 · NCT06653153 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lecanemab's landscape · Remternetug's landscape